Merck and Pfizer commence Phase III trial of ovarian cancer drug avelumab

Merck and Pfizer have commenced the JAVELIN Ovarian 100 Phase III trial of avelumab combined with platinum-based chemotherapy to treat locally advanced or metastatic disease (Stage III or Stage IV) with an untreated epithelial ovarian cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news